Celldex Therapeutics, Inc. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
Celldex Therapeutics, Inc. (CLDX) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$54.34 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-02-25
- Celldex Therapeutics, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was -$54.34M.
- Celldex Therapeutics, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was -$33.15M.
- Celldex Therapeutics, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2023 was -$29.70M.
- Celldex Therapeutics, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2022 was -$23.59M.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month |
|---|---|
| 2025-12-31 | -$54.34M 10-K · filed 2026-02-25 |
| 2024-12-31 | -$33.15M 10-K · filed 2026-02-25 |
| 2023-12-31 | -$29.70M 10-K · filed 2026-02-25 |
| 2022-12-31 | -$23.59M 10-K · filed 2025-02-27 |
| 2021-12-31 | -$14.86M 10-K · filed 2024-02-26 |
| 2020-12-31 | -$12.80M 10-K · filed 2023-02-28 |
| 2019-12-31 | -$10.68M 10-K · filed 2022-02-28 |
| 2018-12-31 | -$31.91M 10-K · filed 2021-03-29 |
| 2017-12-31 | -$39.89M 10-K · filed 2020-03-26 |
| 2016-12-31 | -$43.70M 10-K · filed 2019-03-07 |
| 2015-12-31 | -$43.25M 10-K · filed 2018-03-07 |
| 2014-12-31 | -$40.15M 10-K · filed 2017-03-14 |
| 2013-12-31 | -$27.73M 10-K/A · filed 2016-02-25 |
| 2012-12-31 | -$20.10M 10-K · filed 2015-02-24 |
| 2011-12-31 | -$15.21M 10-K · filed 2014-03-03 |
| 2010-12-31 | -$838.00K 10-K · filed 2013-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |